Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
DRUG:
camizestrant (AZD9833)
i
Other names:
AZD9833, AZD-9833, AZD 9833
Associations
(7)
News
Trials
Company:
AstraZeneca
Associations
(7)
News
Trials
C2 | Sensitive
C3 | Sensitive
D | Sensitive
C2 | Resistant
C3 | Resistant
D | Resistant
Show legend
Group by Gene:
Include preclinical:
Breast Cancer
Estrogen Receptor Positive Breast Cancer
HER2 Negative Breast Cancer
ER positive
C2
ER positive
|
HER2 Negative Breast Cancer
|
AZD9833
[
C2
]
ER positive
|
HER2 Negative Breast Cancer
|
capivasertib + AZD9833
[
C3
]
ESR1 mutation
C2
ESR1 mutation
|
Breast Cancer
|
AZD9833
[
C2
]
C3
ESR1 mutation
|
HER2 Negative Breast Cancer
|
abemaciclib + AZD9833
[
C3
]
ER positive + ESR1 mutation
C3
ER positive + ESR1 mutation
|
HER2 Negative Breast Cancer
|
AZD9833
[
C3
]
ER D538G
D
ER D538G
|
Estrogen Receptor Positive Breast Cancer
|
AZD9833
[
D
]
ER positive + PIK3CA H1047R
D
ER positive + PIK3CA H1047R
|
Breast Cancer
|
AZD9833 + OKI-219
[
D
]
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login